Novo Nordisk ® es care sales growth is driven by GLP-1 patients and value market share in IO Number of patients (millions) Value market share 5 Class growth >50% 75% 62.6% 4 60% 3 41.3% 45% 2 35.3% 30% 1 0 Aug-20 GLP-1 patients Victoza ® Aug-21 Ozempic ® dulaglutide 16.5% 15% 4.3% 0% Aug-22 Rybelsus ® NN GLP-1 rage. GLP-1 class growth calculated as Jun-Aug 2022 vs Jun-Aug 2021 (Rolling 3 month average) wan; RoW: Rest of World; R3M: Rolling three months
Download PDF file